PYC Therapeutics says fourth candidate has potential in polycystic kidney disease

Latest News

PYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimensional human models derived from patients with end-stage renal failure due to autosomal dominant polycystic kidney disease (PKD).

The company said the results demonstrate that an investigational drug candidate designed by PYC - PYC-003 - to treat PKD disease at its root cause is effective.

PYC-003 is the fourth program in the company’s development pipeline – joining three other first-in-class RNA drug candidates with disease-modifying potential currently progressing into or through human trials.

PYC said it now plans to accelerate PYC-003 into human trials.

It said an Investigational New Drug (IND) application to the US FDA to enable trials is planned for the first half of 2024.